SOURCE: Health Enhancement Products, Inc

March 01, 2011 08:30 ET

Health Enhancement Products Leases 10,000 Square Foot State-of-the-Art Production Facility

SCOTTSDALE, AZ--(Marketwire - March 1, 2011) - Health Enhancement Products, Inc. (OTCBB: HEPI) has signed a three year real estate lease in Scottsdale, AZ and will move its operations into the new facility by April 1, 2011.

HEPI will occupy approximately 10,000 square feet of space which will allow the company to house its entire growing and bottling operations under one roof. It will also be home to the Company's new corporate headquarters. The state-of-the-art facility is completely climate controlled to allow the Company to grow, filter and bottle its proprietary ProAlgaZyme® (PAZ™) compound.

The facility, located at 15610 N 83rd Way in Scottsdale, AZ, was previously occupied by a GMP compliant supplement manufacturer. 

John Gorman, HEPI Executive Vice President of Operations, commented, "We are excited to have executed this lease arrangement to house all of our operations including production." Mr. Gorman continued, "The new space is a necessity in order to meet with the growing demand in production orders from our recent agreement with Xooma."

About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB: HEPI) is a health & wellness company engaged in the development of products comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive. The Company's product is ProAlgaZyme® (PAZ™) a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme®.

Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

For more information, please visit

Contact Information

  • Contact:
    David Sasso